200 related articles for article (PubMed ID: 23276893)
1. Efficacy and safety of biologic treatments in Familial Mediterranean Fever.
Akgul O; Kilic E; Kilic G; Ozgocmen S
Am J Med Sci; 2013 Aug; 346(2):137-41. PubMed ID: 23276893
[TBL] [Abstract][Full Text] [Related]
2. A systematic literature review of efficacy, effectiveness and safety of biologic therapies for treatment of familial Mediterranean fever.
Kuemmerle-Deschner JB; Gautam R; George AT; Raza S; Lomax KG; Hur P
Rheumatology (Oxford); 2020 Oct; 59(10):2711-2724. PubMed ID: 32533192
[TBL] [Abstract][Full Text] [Related]
3. Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever.
Şahin A; Derin ME; Albayrak F; Karakaş B; Karagöz Y
Adv Rheumatol; 2020 Jan; 60(1):12. PubMed ID: 32000860
[TBL] [Abstract][Full Text] [Related]
4. Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents.
Eroglu FK; Beşbaş N; Topaloglu R; Ozen S
Rheumatol Int; 2015 Oct; 35(10):1733-7. PubMed ID: 26001859
[TBL] [Abstract][Full Text] [Related]
5. IL-1β biological treatment of familial Mediterranean fever.
Soriano A; Verecchia E; Afeltra A; Landolfi R; Manna R
Clin Rev Allergy Immunol; 2013 Aug; 45(1):117-30. PubMed ID: 23322405
[TBL] [Abstract][Full Text] [Related]
6. Tofacitinib suppresses disease activity and febrile attacks in a patient with coexisting rheumatoid arthritis and familial Mediterranean fever.
Gök K; Cengiz G; Erol K; Ozgocmen S
Acta Reumatol Port; 2017; 42(1):88-90. PubMed ID: 28371574
[TBL] [Abstract][Full Text] [Related]
7. Biologic therapy in familial Mediterranean fever.
Koga T; Migita K; Kawakami A
Mod Rheumatol; 2016 Sep; 26(5):637-41. PubMed ID: 26939747
[TBL] [Abstract][Full Text] [Related]
8. Canakinumab is effective in patients with familial Mediterranean fever resistant and intolerant to the colchicine and/or anakinra treatment.
Karabulut Y; Gezer HH; Duruöz MT
Rheumatol Int; 2022 Jan; 42(1):81-86. PubMed ID: 34550430
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of canakinumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: A single-centre observational study.
Tomokawa T; Koga T; Endo Y; Michitsuji T; Kawakami A
Mod Rheumatol; 2022 Jul; 32(4):797-802. PubMed ID: 34897516
[TBL] [Abstract][Full Text] [Related]
10. Update on the management of colchicine resistant Familial Mediterranean Fever (FMF).
El Hasbani G; Jawad A; Uthman I
Orphanet J Rare Dis; 2019 Oct; 14(1):224. PubMed ID: 31615541
[TBL] [Abstract][Full Text] [Related]
11. Anti-IL1 treatment in colchicine-resistant paediatric FMF patients: real life data from the HELIOS registry.
Sag E; Akal F; Atalay E; Akca UK; Demir S; Demirel D; Batu ED; Bilginer Y; Ozen S
Rheumatology (Oxford); 2020 Nov; 59(11):3324-3329. PubMed ID: 32306038
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of anti-interleukin-1 treatment in familial Mediterranean fever patients: a systematic review and meta-analysis.
Kilic B; Guler Y; Azman FN; Bostanci E; Ugurlu S
Rheumatology (Oxford); 2024 Apr; 63(4):925-935. PubMed ID: 37769252
[TBL] [Abstract][Full Text] [Related]
13. Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders.
Arnold DD; Yalamanoglu A; Boyman O
Front Immunol; 2022; 13():888392. PubMed ID: 35874710
[TBL] [Abstract][Full Text] [Related]
14. The clinical role of anakinra in the armamentarium against familial Mediterranean fever.
Parlar K; Ates MB; Egeli BH; Ugurlu S
Expert Rev Clin Immunol; 2024 May; 20(5):441-453. PubMed ID: 38133629
[TBL] [Abstract][Full Text] [Related]
15. Canakinumab in colchicine resistant familial Mediterranean fever and other pediatric rheumatic diseases.
Çakan M; Karadağ ŞG; Ayaz NA
Turk J Pediatr; 2020; 62(2):167-174. PubMed ID: 32419407
[TBL] [Abstract][Full Text] [Related]
16. Total Hip Joint Replacement in a Patient with Colchicine-Resistant Familial Mediterranean Fever under Canakinumab Treatment.
Matsumoto H; Ohashi H; Fujita Y; Yoshida S; Yokose K; Temmoku J; Matsuoka N; Shinden Y; Kusano K; Sonobe T; Nakamoto Y; Yashiro-Furuya M; Asano T; Sato S; Suzuki E; Yago T; Watanabe H; Migita K
Tohoku J Exp Med; 2022 Feb; 256(2):169-174. PubMed ID: 35236806
[TBL] [Abstract][Full Text] [Related]
17. Anti-TNF agents in familial Mediterranean fever: report of three cases and review of the literature.
Ozgocmen S; Akgul O
Mod Rheumatol; 2011 Dec; 21(6):684-90. PubMed ID: 21567247
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of Canakinumab Treatment in Recipients of Kidney Transplant With Familial Mediterranean Fever: A Case Series.
Sendogan DO; Saritas H; Kumru G; Eyupoglu S; Sadioglu RE; Tuzuner A; Sengul S; Keven K
Transplant Proc; 2019 Sep; 51(7):2292-2294. PubMed ID: 31400972
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of long-term treatment with intravenous colchicine for familial Mediterranean fever (FMF) refractory to oral colchicine.
Grossman C; Farberov I; Feld O; Livneh A; Ben-Zvi I
Rheumatol Int; 2019 Mar; 39(3):517-523. PubMed ID: 30604205
[TBL] [Abstract][Full Text] [Related]
20. Treatment of familial mediterranean fever with canakinumab in patients who are unresponsive to colchicine.
Berdeli A; Şenol Ö; Talay G
Eur J Rheumatol; 2019 Apr; 6(2):85-88. PubMed ID: 31365342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
